FLUROCITABINE HYDROCHLORIDE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C9H10FN3O4.ClH
Molecular Weight	279.653
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of FLUROCITABINE HYDROCHLORIDE

Structure Search

SMILES

Cl.OC[C@H]1O[C@@H]2[C@@H](OC3=NC(=N)C(F)=C[N@@]23)[C@@H]1O

InChI

InChIKey=RMCFDHVUFKPQRX-CFHSPSGHSA-N

InChI=1S/C9H10FN3O4.ClH/c10-3-1-13-8-6(5(15)4(2-14)16-8)17-9(13)12-7(3)11;/h1,4-6,8,11,14-15H,2H2;1H/t4-,5-,6+,8-;/m1./s1

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C9H10FN3O4
Molecular Weight	243.1918
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1149046
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/348088

Flurocitabine is an anti-metabolite that was developed by Hoffmann-La Roche for the treatment of cancer. The drug is metabolized to 2 biologically active substances, AFC (1-beta-D-arabinofuranosyl-5-fluorocytosine) and AFU (arabinofuranosyl-5-fluorouracil). Flurocitabine was tested against stomach cancer, pancreatic cancer, small cell lung cancer and AML, however, the development was terminated in the early phases.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
DNA polymerase 2 Target ID: DNA polymerase Sources: http://link.springer.com/chapter/10.1007%2F978-1-4613-4352-3_67	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Gastric cancer 53 Sources: https://www.ncbi.nlm.nih.gov/pubmed/93030	Primary	Phase II 1147	Unknown Approved Use Unknown
Pancreatic cancer 98 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6159121	Primary	Phase II 1147	Unknown Approved Use Unknown
Acute non-lymphocytic leukemia 10 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6170414	Primary	Phase I 438	Unknown Approved Use Unknown
Small-cell lung cancer 41 Sources: http://ascopubs.org/doi/pdf/10.1200/jco.1992.10.3.484	Primary	Phase II 1147	Unknown Approved Use Unknown

Sourcing

Vendor/Aggregator	ID	URL
BOC Sciences	37717-21-8	http://www.bocsci.com/description.asp?cas=37717-21-8
Compound Cloud	3034016
eMolecules	110015564	https://orderbb.emolecules.com/search/#?query=110015564

PubMed

Title	Date	PubMed
Anhydro-ara-5-fluorocytidine (AAFC) in gastrointestinal cancer. A phase II study.	1980	6159121
Phase II study of anhydro-ara-5-fluorocytidine in adenocarcinoma of gastrointestinal tract, epidermoid carcinoma of lung, head and neck, breast carcinoma and small cell anaplastic carcinoma of lung. A study report of the E.O.R.T.C. early clinical trial cooperative group.	1978-02	75105
Phase I and II clinical study of anhydro-ara-5-fluorocytosine (AAFC) and ICRF-159 combination in adenocarcinoma of digestive origin.	1978	93030
Comparative ultrastructure of submaxillary salivary glands from mice treated with cytosine arabinoside, cyclocytidine, and anhydro-ara-5-fluorocytidine.	1976-07	64296
Phase I study of weekly administration of anhydroara-5-fluorocytidine (NSC-166641).	1976-03	1260783
Physiological disposition of 2,2'-anhydro-1-beta-D-arabinofuranosyl-5-fluorocytosine in humans.	1975-09	1149046

Patents

Sample Use Guides

In Vivo Use Guide

The maximum tolerated dose is 650 mg/m2 I.V. weekly (stomach cancer). In acute nonlymphocytic leukemia the dose is 800 mg/m2 (600mg/m2 in children) given every 12 hours until marrow hypocellularity is achieved. In Small-Cell Lung Cancer the dose is 15-20 mg/m2 IV given daily for 5 days every 3 weeks or 33-40 mg/m2 IV given weekly.

Route of Administration: Intravenous

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 22:22:46 GMT 2025` Edited by `admin` on `Mon Mar 31 22:22:46 GMT 2025`
Record UNII	386064MQOR
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

NSC-166641

Preferred Name

English

FLUROCITABINE HYDROCHLORIDE

Common Name

English

5-F-ANHYDRO-ARA-C HYDROCHLORIDE

Common Name

English

2,2'-ANHYDRO-1-BETA-D-ARABINOFURANOSYL-5-FLUOROCYTOSINE

Common Name

English

6H-FURO(2',3':4,5)OXAZOLO(3,2-A)PYRIMIDINE-2-METHANOL, 7-FLUORO-2,3,3A,9A-TETRAHYDRO-3-HYDROXY-6-IMINO-, HYDROCHLORIDE (1:1), (2R,3R,3AS,9AR)-

Systematic Name

English

RO-21-0702

Code

English

RO 21-0702

Code

English

6H-FURO(2',3':4,5)OXAZOLO(3,2-A)PYRIMIDINE-2-METHANOL, 7-FLUORO-2,3,3A,9A-TETRAHYDRO-3-HYDROXY-6-IMINO-, MONOHYDROCHLORIDE, (2R-(2.ALPHA.,3.BETA.,3A.BETA.,9A.BETA.))-

Systematic Name

English

6H-FURO(2',3':4,5)OXAZOLO(3,2-A)PYRIMIDINE-2-METHANOL, 7-FLUORO-2,3,3A,9A-TETRAHYDRO-3-HYDROXY-6-IMINO-, MONOHYDROCHLORIDE, (2R,3R,3AS,9AR)-

Systematic Name

English

Code System Code Type Description

FDA UNII

386064MQOR